A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Oct 2007 Status changed from in progress to discontinued
- 28 Dec 2006 Status change
- 27 Nov 2005 New trial record.